BioNTech SE (DE:22UA)
XETRA:22UA
22UA Stock Chart & Stats
€77.65
-€3.00(-2.44%)
At close: 4:00 PM EST
€77.65
-€3.00(-2.44%)
Day’s Range― - ―
52-Week Range€68.30 - €110.90
Previous CloseN/A
Volume65.30K
Average Volume (3M)90.74K
Market Cap
€19.45B
Enterprise Value€11.96B
Total Cash (Recent Filing)€14.83B
Total Debt (Recent Filing)€267.29M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
May 11, 2026EPS Estimate
-2.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.25
Shares Outstanding252,531,940
10 Day Avg. Volume44,544
30 Day Avg. Volume90,744
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)1.02
Price to Sales (P/S)7.10
P/FCF Ratio72.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€118.46Price Target Upside52.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
EPS Forecast (FY)-3.76
Revenue Forecast (FY)€1.96B
Bulls Say, Bears Say
Bulls Say
Clinical Trial EfficacyStrong Phase 2 data for pumitamig showing improved survival in patients with higher PD-L1 expression supports confidence in the drug's clinical activity and bolsters the case for larger pivotal trials.
Combination Therapy PotentialPreclinical and early clinical evidence that the pumitamig plus BNT326 combination delivers superior anti-tumor activity suggests a route to differentiated combination regimens and expanded indication opportunities.
Financial Runway And ValuationA substantial cash position relative to enterprise value, along with modest operating expense guidance, could provide the financial runway to fund late-stage oncology programs and pursue value-accretive deals.
Bears Say
Leadership UncertaintyDeparture of the founding CEO and CMO creates leadership uncertainty while multiple important clinical readouts are pending, which may weaken investor confidence and increase stock volatility.
Regulatory And Execution RiskChallenges around confirmatory trial enrollment, domestic patient representation, and historical trial failures in some oncology indications raise the risk of regulatory setbacks and missed milestones.
Revenue Pressure From COVID BusinessDeclining COVID vaccine sales and softer revenue guidance heighten reliance on pipeline success for future growth and make the stock more sensitive to near-term clinical outcomes.
BioNTech SE News
22UA FAQ
What was BioNTech SE’s price range in the past 12 months?
BioNTech SE lowest stock price was €68.30 and its highest was €110.90 in the past 12 months.
What is BioNTech SE’s market cap?
BioNTech SE’s market cap is €19.45B.
When is BioNTech SE’s upcoming earnings report date?
BioNTech SE’s upcoming earnings report date is May 11, 2026 which is in 39 days.
How were BioNTech SE’s earnings last quarter?
BioNTech SE released its earnings results on Mar 10, 2026. The company reported -€1.25 earnings per share for the quarter, missing the consensus estimate of -€0.162 by -€1.088.
Is BioNTech SE overvalued?
According to Wall Street analysts BioNTech SE’s price is currently Undervalued.
Does BioNTech SE pay dividends?
BioNTech SE does not currently pay dividends.
What is BioNTech SE’s EPS estimate?
BioNTech SE’s EPS estimate is -2.19.
How many shares outstanding does BioNTech SE have?
BioNTech SE has 252,531,940 shares outstanding.
What happened to BioNTech SE’s price movement after its last earnings report?
BioNTech SE reported an EPS of -€1.25 in its last earnings report, missing expectations of -€0.162. Following the earnings report the stock price went down -20.771%.
Which hedge fund is a major shareholder of BioNTech SE?
Currently, no hedge funds are holding shares in DE:22UA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BioNTech SE Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€118.46 (52.56% Upside)
€118.46 (52.56% Upside)
Blogger Sentiment
Bullish
DE:22UA Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Sold Shares
Worth $106.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-10.21%
12-Months-Change
Fundamentals
Return on Equity
-6.03%
Trailing 12-Months
Asset Growth
10.69%
Trailing 12-Months
Company Description
BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
22UA Company Deck
22UA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presented a constructive picture: BioNTech outperformed its raised 2025 guidance, preserved a very strong cash position (EUR 17.2 billion), advanced a broad late-stage oncology pipeline with multiple planned readouts in 2026–2030, and executed strategic deals to derisk programs. Offsetting this, management guided materially lower revenues for 2026 (EUR 2.0–2.3bn vs EUR 2.9bn in 2025), highlighted near-term increases in R&D and SG&A to support oncology launches, reported an adjusted net loss (EUR 117m) and disclosed a trial discontinuation in one indication. The founders' planned transition to a new company introduces execution uncertainty but is framed as an orderly process through end-2026. On balance, the positive operational progress, portfolio de-risking and very strong liquidity outweigh the near-term revenue headwinds and costs.View all DE:22UA earnings summaries22UA Stock 12 Month Forecast
Average Price Target
€118.46
▲(52.56% Upside)
Technical Analysis
Options Prices
Currently, No data available
---